Switch Projected To Continue Driving OTC Market Growth In 5-Year Picture
This article was originally published in The Tan Sheet
Executive Summary
Market researchers see multiple factors affecting the outlook for Rx-to-OTC switches, which remain the biggest growth driver in the nonprescription arena
You may also be interested in...
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
Pharma Firms Stir OTC Market, FDA Hones Enforcement: Top Stories Of 2009
Firms entering or expanding their presence in the OTC drug and nutritional product markets as part of pharmaceutical industry shuffling in 2009 attracted the attention of stakeholders already competing in those markets
The JUPITER Results: Will The Planets Align For OTC Statins?
AstraZeneca's JUPITER trial onCrestor (rosuvastatin) greatly expands the pool of patients who may benefit from statin use, which could help make the case for an OTC switch in the cholesterol-lowering class in the future